FDA Approves Enzeevu, a Biosimilar to Eylea
Sandoz has announced the US Food and Drug Administration (FDA) approved Enzeevu (aflibercept-abzv) 2mg vial kit and pre-filled syringe for intravitreal injection. Enzeevu is indicated to improve and maintain visual acuity in patients with neovascular age-related macular degeneration (nAMD). In addition, the FDA provisionally determined Enzeevu would be interchangeable with the reference medicine, as it is currently subject to unexpired exclusivity for the first interchangeable biosimilar products.
- nAMD, also known as wet AMD, is a subtype of age-related macular degeneration (AMD), which is a leading cause of vision impairment in patients over 50 years in North America.
Source: Sandoz
